Rutgers University has launched a clinical trial to test the safety and efficacy of a new drug that could help prevent serious illness and death in early-stage COVID-19 patients. The drug is called EDP1815. It is administered orally, and is said to be anti-inflammatory and very safe. It will be given to newly hospitalized COVID-19 patients at Robert Wood Johnson University Hospital. They hope to determine if it can regulate the onslaught of something called “cytokine storms,” which cause the immune system to attack organs, such as the lungs, which lead to the immune system malfunctioning and become deadly – and is the reason for severe cases of respiratory distress and death. To read the full story.
Home / News / Rutgers clinical trial: New drug could help prevent serious illness, death in early-stage COVID-19 patients
Recent Posts
- Majority of New Jerseyans Worried About Medical and Health Care Costs.
- NJACTS Community Engagement Core COVID-19 Resources
- With Drowning for Children on the Rise, a Rutgers Heath Expert Discusses Water Safety.
- Researcher Teams Up With Teen Champion Figure Skater to Discover Potential Treatments for Addiction Disorders.
- New Jersey Ranks Near the Bottom on Pay Equity for Mothers.
Categories
- Community (1,934)
- Covid (970)
- CTO Events (1)
- News (2,477)
- Pilots (20)